Literature DB >> 8033815

Characterization of unique binding kinetics of follistatin and activin or inhibin in serum.

A L Schneyer1, D A Rzucidlo, P M Sluss, W F Crowley.   

Abstract

Serum binding proteins (BPs) have been identified for several peptide and protein hormones, and their presence has significant implications for the biological action of the hormone. Follistatin (FS) has been identified as an activin- and inhibin-BP in tissues, serum, and follicular fluid of several species, including humans. In this study, the binding kinetics of FS for activin and inhibin were characterized in human serum using gel filtration chromatography and compared to those of pure recombinant hormones using chromatography and a new solid phase assay. When complexed with radiolabeled activin or inhibin, FS eluted at a volume corresponding to a mol wt range of 67,000-150,000, an elution volume identical to the lower mol wt BP peak observed in serum. Furthermore, kinetic analyses of recombinant FS binding to activin using a solid phase assay revealed that 1) the FS-activin interaction is of high affinity, similar to or exceeding that estimated for activin binding to its receptor; 2) binding to activin is essentially irreversible at physiological pH; and 3) the potency of inhibin is approximately 500- to 1000-fold lower than that of activin in the FS binding assay. The lack of FS-[125I]activin complex reversibility observed in the solid phase assay was confirmed using a modified gel filtration chromatography protocol. Thus, preincubation of pure FS or serum with unlabeled activin for 2 h eliminated all binding of subsequently added labeled activin despite a much longer incubation period. However, when labeled activin was incubated with FS for 2 h, subsequent addition of unlabeled activin or inhibin was unable to displace labeled activin from FS, again demonstrating a lack of reversibility. Finally, to map this high affinity interaction, overlapping synthetic peptides were used to compete with labeled activin for FS binding. Two potential contact sites between FS and activin were identified, one near the N-terminus (amino acids 15-29) and the other near the C-terminus (amino acids 99-116). Given its apparently irreversible nature, high affinity, and ability to neutralize activin's biological activity, FS is quite different from the typical hormone-BP. These unique properties of FS undoubtedly attest to the potency of activin in many physiological and developmental settings and, therefore, to the importance of BPs, such as FS for regulating activin's bioactivity, distribution, and/or clearance.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8033815     DOI: 10.1210/endo.135.2.8033815

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  17 in total

1.  Characterization of follistatin-type domains and their contribution to myostatin and activin A antagonism.

Authors:  Jennifer N Cash; Elizabeth B Angerman; Henry T Keutmann; Thomas B Thompson
Journal:  Mol Endocrinol       Date:  2012-05-16

Review 2.  The role of activin in mammary gland development and oncogenesis.

Authors:  Karen A Dunphy; Alan L Schneyer; Mary J Hagen; D Joseph Jerry
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-04-08       Impact factor: 2.673

3.  Inhibin α-subunit N terminus interacts with activin type IB receptor to disrupt activin signaling.

Authors:  Jie Zhu; S Jack Lin; Chao Zou; Yogeshwar Makanji; Theodore S Jardetzky; Teresa K Woodruff
Journal:  J Biol Chem       Date:  2012-01-20       Impact factor: 5.157

Review 4.  Agonists and Antagonists of TGF-β Family Ligands.

Authors:  Chenbei Chang
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-08-01       Impact factor: 10.005

5.  Structure of myostatin·follistatin-like 3: N-terminal domains of follistatin-type molecules exhibit alternate modes of binding.

Authors:  Jennifer N Cash; Elizabeth B Angerman; Chandramohan Kattamuri; Kristof Nolan; Huaying Zhao; Yisrael Sidis; Henry T Keutmann; Thomas B Thompson
Journal:  J Biol Chem       Date:  2011-11-03       Impact factor: 5.157

6.  Foxg1 promotes olfactory neurogenesis by antagonizing Gdf11.

Authors:  Shimako Kawauchi; Joon Kim; Rosaysela Santos; Hsiao-Huei Wu; Arthur D Lander; Anne L Calof
Journal:  Development       Date:  2009-03-18       Impact factor: 6.868

Review 7.  Regulation of the ovarian reserve by members of the transforming growth factor beta family.

Authors:  Stephanie A Pangas
Journal:  Mol Reprod Dev       Date:  2012-09-11       Impact factor: 2.609

Review 8.  Activins and activin antagonists in hepatocellular carcinoma.

Authors:  Alev Deli; Emanuel Kreidl; Stefan Santifaller; Barbara Trotter; Katja Seir; Walter Berger; Rolf Schulte-Hermann; Chantal Rodgarkia-Dara; Michael Grusch
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

Review 9.  The biology of activin: recent advances in structure, regulation and function.

Authors:  Yin Xia; Alan L Schneyer
Journal:  J Endocrinol       Date:  2009-03-09       Impact factor: 4.286

10.  Differential antagonism of activin, myostatin and growth and differentiation factor 11 by wild-type and mutant follistatin.

Authors:  Alan L Schneyer; Yisrael Sidis; Anisha Gulati; Jie L Sun; Henry Keutmann; Philip A Krasney
Journal:  Endocrinology       Date:  2008-06-05       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.